The Money TrailApril 2, 2026via SiliconAngle
Generare raises $23.2M to discover unknown molecules and advance new drugs
Why it matters
AI-powered drug discovery is attracting serious capital as biotech companies race to generate novel molecular data that could revolutionize pharmaceutical development timelines and success rates.
Key signals
- $23.2M Series A funding round
- €20 million raised
- Founded in 2023
- Co-led by Alven and Daphni
- Paris-based biotechnology company
- Uses AI for drug development and molecular discovery
The hook
$23.2M. That's what AI biotech startup Generare just raised to discover molecules that have never existed before.
Generare Bioscience SAS, a Paris-based biotechnology company generating never-before-seen molecular data for drug development using artificial intelligence, announced today it has raised €20 million, about $23.3 million, in an early-stage funding round co-led by Alven and Daphni. All existing investors, including Galion.exe, Teampact Ventures and Vives Partners, joined the Series A round. Founded in 2023, […]
The post Generare raises $23.2M to discover unknown molecules and advance new drugs appeared first on SiliconANGLE.
Relevance score:85/100